Adial Pharmaceuticals strengthens its patent portfolio with the issuance of a new US patent covering AD04's potential for treating opioid use disorder through targeting the serotonin transporter gene.
Wednesday, Adial Pharmaceuticals Inc (NASDAQ:ADIL) announced patent number 11,905,562 was issued on February 20, 2024, by the United States Patent and Trademark Office. The patent covers the company’s lead investigational new drug product, AD04, and its ability to target the serotonin transporter gene for the potential treatment of opioid use disorder. The company says the new patent strengthens Adial’s patent portfolio and covers AD04’s ability to target the serotonin transporter gene for the p
28.02.2024 - New patent strengthens Adial’s patent portfolio and covers AD04’s unique ability to target the serotonin transporter gene for the potential treatment of opioid use disorderCHARLOTTESVILLE, Va., Feb. 28, 2024 (GLOBE NEWSWIRE) - Adial . Seite 1
Adial Pharmaceuticals said the patent was awarded by the United States Patent and Trademark Office on Feb. 20 and covers the company's lead investigational new drug product, AD04, and its ability to target the serotonin transporter gene for the potential treatment of opioid use disorder. Benzinga broke the news first Wednesday morning with an exclusive report before the opening bell.
Adial Pharmaceuticals US patent, enhancing genetic diagnostic coverage for tailored treatment of alcohol and drug dependencies, including opioid use disorder. Learn more about AD04's potential in addressing a $40 billion U